Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1988-08

AUTHORS

Andreas Supersaxo, Wayne Hein, Harald Gallati, Hans Steffen

ABSTRACT

The effect of different parenteral administration routes (i.d., s.c., i.v.), infusion rates, and albumin contents of the drug vehicle on the cumulative recovery of recombinant human interferon alpha-2a (rIFN alpha-2a) in lymph and on its concentration in blood and lymph was determined in sheep. Blood samples were withdrawn from a jugular vein catheter and lymph was collected from a cannulated efferent popliteal lymphatic duct. The concentration of rIFN alpha-2a in lymph and blood plasma samples was measured by an enzyme immunoassay. Following i.v. infusion of 2 x 10(7) U of rIFN alpha-2a, the peak concentrations measured in blood plasma and lymph, respectively, were 8250 and 14 U/ml. The concentration measured in lymph after i.d. or s.c. administration of the same dose was about 10(5) times higher (peak concentration, 3.1 x 10(6) U/ml), while blood plasma levels remained low (peak concentration, 315 U/ml). The cumulative recovery of rIFN alpha-2a in lymph following i.d. or s.c. administration was 59.2 +/- 7% (mean +/- SD; N = 8) and was affected neither by the infusion rate nor by the coadministration of albumin. Our data indicate that following i.d. or s.c. administration, rIFN alpha-2a (MW 19,000) is absorbed mainly by the lymphatics. This results in high levels of rIFN alpha-2a in the lymph which drains from the application site to the regional lymph nodes. The knowledge gained in this investigation may help to improve the mode of administration and therapeutic efficacy of protein drugs whose targets are lymphoid cells. More... »

PAGES

472-476

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1015957022073

DOI

http://dx.doi.org/10.1023/a:1015957022073

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1045641677

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/3244653


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Absorption", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intradermal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Subcutaneous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon Type I", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymph", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoid Tissue", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Serum Albumin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sheep", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Roche (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "Pharmaceutical Research/Preclinical Development, F. Hoffmann-La Roche & Co. Ltd, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Supersaxo", 
        "givenName": "Andreas", 
        "id": "sg:person.01263702367.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263702367.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Basilea Pharmaceutica (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.418234.8", 
          "name": [
            "Basel Institute for Immunology, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hein", 
        "givenName": "Wayne", 
        "id": "sg:person.0753747224.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753747224.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "Central Research Units, F. Hoffmann-La Roche & Co. Ltd, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gallati", 
        "givenName": "Harald", 
        "id": "sg:person.01200100054.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200100054.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "Pharmaceutical Research/Preclinical Development, F. Hoffmann-La Roche & Co. Ltd, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Steffen", 
        "givenName": "Hans", 
        "id": "sg:person.01247014417.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247014417.99"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/0306-3623(86)90189-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001818489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0306-3623(86)90189-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001818489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/bpb1978.7.59", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005279663"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0306-3623(86)90017-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005628349"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0306-3623(86)90017-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005628349"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1016377114477", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008981868", 
          "https://doi.org/10.1023/a:1016377114477"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/bpb1978.8.206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011665258"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19860415)57:8+<1648::aid-cncr2820571303>3.0.co;2-o", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012261851"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02118644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012918196", 
          "https://doi.org/10.1007/bf02118644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02118644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012918196", 
          "https://doi.org/10.1007/bf02118644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0167-5699(85)90159-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017875411"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1113/expphysiol.1962.sp001620", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031555789"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1084/jem.121.6.901", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040893216"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0003-9861(83)90118-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043004064"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(86)90168-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044279461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(86)90168-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044279461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1016349605061", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045321048", 
          "https://doi.org/10.1023/a:1016349605061"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/cdd.1984.1.337", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059243547"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078798623", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081946813", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1988-08", 
    "datePublishedReg": "1988-08-01", 
    "description": "The effect of different parenteral administration routes (i.d., s.c., i.v.), infusion rates, and albumin contents of the drug vehicle on the cumulative recovery of recombinant human interferon alpha-2a (rIFN alpha-2a) in lymph and on its concentration in blood and lymph was determined in sheep. Blood samples were withdrawn from a jugular vein catheter and lymph was collected from a cannulated efferent popliteal lymphatic duct. The concentration of rIFN alpha-2a in lymph and blood plasma samples was measured by an enzyme immunoassay. Following i.v. infusion of 2 x 10(7) U of rIFN alpha-2a, the peak concentrations measured in blood plasma and lymph, respectively, were 8250 and 14 U/ml. The concentration measured in lymph after i.d. or s.c. administration of the same dose was about 10(5) times higher (peak concentration, 3.1 x 10(6) U/ml), while blood plasma levels remained low (peak concentration, 315 U/ml). The cumulative recovery of rIFN alpha-2a in lymph following i.d. or s.c. administration was 59.2 +/- 7% (mean +/- SD; N = 8) and was affected neither by the infusion rate nor by the coadministration of albumin. Our data indicate that following i.d. or s.c. administration, rIFN alpha-2a (MW 19,000) is absorbed mainly by the lymphatics. This results in high levels of rIFN alpha-2a in the lymph which drains from the application site to the regional lymph nodes. The knowledge gained in this investigation may help to improve the mode of administration and therapeutic efficacy of protein drugs whose targets are lymphoid cells.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1023/a:1015957022073", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094644", 
        "issn": [
          "0724-8741", 
          "1573-904X"
        ], 
        "name": "Pharmaceutical Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "name": "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", 
    "pagination": "472-476", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d969a07ad3ec981202dfe1f1ff7baffc056bddb3e9abb6741cbb81cb9d3c9871"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "3244653"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8406521"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1015957022073"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1045641677"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1015957022073", 
      "https://app.dimensions.ai/details/publication/pub.1045641677"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T01:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000507.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1023/A:1015957022073"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1015957022073'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1015957022073'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1015957022073'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1015957022073'


 

This table displays all metadata directly associated to this object as RDF triples.

203 TRIPLES      21 PREDICATES      60 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1015957022073 schema:about N0981e01e84ee4bbd93c8f5ebc2a2c24b
2 N1d11d2845fcf470aa3cd9609ccbf4c50
3 N2da035285b814cf791e9d905425b6061
4 N30b99166069444ba9ba015a815c74076
5 N351308e12380456595197f5c2b683314
6 N35722ce6cca442b0a2332ef8ad625c0a
7 N3e8d02e1b65a44d094fe8d1c150c2bb9
8 N6b107e4f812b4539a69c97e22d319c25
9 Na75652fbccc64c9b8af8fc5f477ee878
10 Na91937c3123d43939e7fd845b68d6469
11 Nb9a7afe6811d4ea895a97679c2858157
12 Nbce6f48384ea417d92bf96d2149ef11f
13 Nc1c13ab3afab4bb2ae9fa1313ca5580a
14 Nc8965111252f41a28ef1382d01bd919c
15 Nf814391b74db44a5976cdd88fa874026
16 anzsrc-for:11
17 anzsrc-for:1102
18 schema:author N3b5b090ecb1f43f9bb32626f65b32dfe
19 schema:citation sg:pub.10.1007/bf02118644
20 sg:pub.10.1023/a:1016349605061
21 sg:pub.10.1023/a:1016377114477
22 https://app.dimensions.ai/details/publication/pub.1078798623
23 https://app.dimensions.ai/details/publication/pub.1081946813
24 https://doi.org/10.1002/1097-0142(19860415)57:8+<1648::aid-cncr2820571303>3.0.co;2-o
25 https://doi.org/10.1016/0003-9861(83)90118-2
26 https://doi.org/10.1016/0167-5699(85)90159-8
27 https://doi.org/10.1016/0306-3623(86)90017-0
28 https://doi.org/10.1016/0306-3623(86)90189-8
29 https://doi.org/10.1016/0378-5173(86)90168-7
30 https://doi.org/10.1084/jem.121.6.901
31 https://doi.org/10.1089/cdd.1984.1.337
32 https://doi.org/10.1113/expphysiol.1962.sp001620
33 https://doi.org/10.1248/bpb1978.7.59
34 https://doi.org/10.1248/bpb1978.8.206
35 schema:datePublished 1988-08
36 schema:datePublishedReg 1988-08-01
37 schema:description The effect of different parenteral administration routes (i.d., s.c., i.v.), infusion rates, and albumin contents of the drug vehicle on the cumulative recovery of recombinant human interferon alpha-2a (rIFN alpha-2a) in lymph and on its concentration in blood and lymph was determined in sheep. Blood samples were withdrawn from a jugular vein catheter and lymph was collected from a cannulated efferent popliteal lymphatic duct. The concentration of rIFN alpha-2a in lymph and blood plasma samples was measured by an enzyme immunoassay. Following i.v. infusion of 2 x 10(7) U of rIFN alpha-2a, the peak concentrations measured in blood plasma and lymph, respectively, were 8250 and 14 U/ml. The concentration measured in lymph after i.d. or s.c. administration of the same dose was about 10(5) times higher (peak concentration, 3.1 x 10(6) U/ml), while blood plasma levels remained low (peak concentration, 315 U/ml). The cumulative recovery of rIFN alpha-2a in lymph following i.d. or s.c. administration was 59.2 +/- 7% (mean +/- SD; N = 8) and was affected neither by the infusion rate nor by the coadministration of albumin. Our data indicate that following i.d. or s.c. administration, rIFN alpha-2a (MW 19,000) is absorbed mainly by the lymphatics. This results in high levels of rIFN alpha-2a in the lymph which drains from the application site to the regional lymph nodes. The knowledge gained in this investigation may help to improve the mode of administration and therapeutic efficacy of protein drugs whose targets are lymphoid cells.
38 schema:genre research_article
39 schema:inLanguage en
40 schema:isAccessibleForFree false
41 schema:isPartOf N2ecd2b7b58cc4041bdd869da415517dd
42 N32410904f8bf47f8ac92e0cf9eefceb7
43 sg:journal.1094644
44 schema:name Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application
45 schema:pagination 472-476
46 schema:productId N12e0f8f2feca4fe58fbf4c531fda19b4
47 N23c08e2f17f14a569fb011a13430e073
48 N491e88dd8aa7495289a1ce5e66dcc2fd
49 Nbe43d7925ad842f3b5220469fc7bfda6
50 Nf2bfd959d37346a981e1b569dff13cba
51 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045641677
52 https://doi.org/10.1023/a:1015957022073
53 schema:sdDatePublished 2019-04-11T01:59
54 schema:sdLicense https://scigraph.springernature.com/explorer/license/
55 schema:sdPublisher Nd76d03913bad473c908d2422a2233c29
56 schema:url http://link.springer.com/10.1023/A:1015957022073
57 sgo:license sg:explorer/license/
58 sgo:sdDataset articles
59 rdf:type schema:ScholarlyArticle
60 N0981e01e84ee4bbd93c8f5ebc2a2c24b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Infusions, Intravenous
62 rdf:type schema:DefinedTerm
63 N0eac431ccd99458886765ee19d82e16b rdf:first sg:person.01247014417.99
64 rdf:rest rdf:nil
65 N12e0f8f2feca4fe58fbf4c531fda19b4 schema:name dimensions_id
66 schema:value pub.1045641677
67 rdf:type schema:PropertyValue
68 N1d11d2845fcf470aa3cd9609ccbf4c50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Time Factors
70 rdf:type schema:DefinedTerm
71 N23c08e2f17f14a569fb011a13430e073 schema:name doi
72 schema:value 10.1023/a:1015957022073
73 rdf:type schema:PropertyValue
74 N2da035285b814cf791e9d905425b6061 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Animals
76 rdf:type schema:DefinedTerm
77 N2ecd2b7b58cc4041bdd869da415517dd schema:issueNumber 8
78 rdf:type schema:PublicationIssue
79 N30b99166069444ba9ba015a815c74076 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Interferon-alpha
81 rdf:type schema:DefinedTerm
82 N32410904f8bf47f8ac92e0cf9eefceb7 schema:volumeNumber 5
83 rdf:type schema:PublicationVolume
84 N351308e12380456595197f5c2b683314 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Injections, Intradermal
86 rdf:type schema:DefinedTerm
87 N35722ce6cca442b0a2332ef8ad625c0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Interferon Type I
89 rdf:type schema:DefinedTerm
90 N3b5b090ecb1f43f9bb32626f65b32dfe rdf:first sg:person.01263702367.82
91 rdf:rest Nfeec1ad7b4504833a34e6fba6ec29689
92 N3e8d02e1b65a44d094fe8d1c150c2bb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Lymph
94 rdf:type schema:DefinedTerm
95 N425610be9e78495faeb75837cc312463 rdf:first sg:person.01200100054.05
96 rdf:rest N0eac431ccd99458886765ee19d82e16b
97 N491e88dd8aa7495289a1ce5e66dcc2fd schema:name pubmed_id
98 schema:value 3244653
99 rdf:type schema:PropertyValue
100 N6b107e4f812b4539a69c97e22d319c25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Injections, Subcutaneous
102 rdf:type schema:DefinedTerm
103 Na75652fbccc64c9b8af8fc5f477ee878 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Lymphoid Tissue
105 rdf:type schema:DefinedTerm
106 Na91937c3123d43939e7fd845b68d6469 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Recombinant Proteins
108 rdf:type schema:DefinedTerm
109 Nb9a7afe6811d4ea895a97679c2858157 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Female
111 rdf:type schema:DefinedTerm
112 Nbce6f48384ea417d92bf96d2149ef11f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Sheep
114 rdf:type schema:DefinedTerm
115 Nbe43d7925ad842f3b5220469fc7bfda6 schema:name nlm_unique_id
116 schema:value 8406521
117 rdf:type schema:PropertyValue
118 Nc1c13ab3afab4bb2ae9fa1313ca5580a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Humans
120 rdf:type schema:DefinedTerm
121 Nc8965111252f41a28ef1382d01bd919c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Serum Albumin
123 rdf:type schema:DefinedTerm
124 Nd76d03913bad473c908d2422a2233c29 schema:name Springer Nature - SN SciGraph project
125 rdf:type schema:Organization
126 Nf2bfd959d37346a981e1b569dff13cba schema:name readcube_id
127 schema:value d969a07ad3ec981202dfe1f1ff7baffc056bddb3e9abb6741cbb81cb9d3c9871
128 rdf:type schema:PropertyValue
129 Nf814391b74db44a5976cdd88fa874026 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Absorption
131 rdf:type schema:DefinedTerm
132 Nfeec1ad7b4504833a34e6fba6ec29689 rdf:first sg:person.0753747224.17
133 rdf:rest N425610be9e78495faeb75837cc312463
134 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
135 schema:name Medical and Health Sciences
136 rdf:type schema:DefinedTerm
137 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
138 schema:name Cardiorespiratory Medicine and Haematology
139 rdf:type schema:DefinedTerm
140 sg:journal.1094644 schema:issn 0724-8741
141 1573-904X
142 schema:name Pharmaceutical Research
143 rdf:type schema:Periodical
144 sg:person.01200100054.05 schema:affiliation https://www.grid.ac/institutes/grid.417570.0
145 schema:familyName Gallati
146 schema:givenName Harald
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200100054.05
148 rdf:type schema:Person
149 sg:person.01247014417.99 schema:affiliation https://www.grid.ac/institutes/grid.417570.0
150 schema:familyName Steffen
151 schema:givenName Hans
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247014417.99
153 rdf:type schema:Person
154 sg:person.01263702367.82 schema:affiliation https://www.grid.ac/institutes/grid.417570.0
155 schema:familyName Supersaxo
156 schema:givenName Andreas
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263702367.82
158 rdf:type schema:Person
159 sg:person.0753747224.17 schema:affiliation https://www.grid.ac/institutes/grid.418234.8
160 schema:familyName Hein
161 schema:givenName Wayne
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753747224.17
163 rdf:type schema:Person
164 sg:pub.10.1007/bf02118644 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012918196
165 https://doi.org/10.1007/bf02118644
166 rdf:type schema:CreativeWork
167 sg:pub.10.1023/a:1016349605061 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045321048
168 https://doi.org/10.1023/a:1016349605061
169 rdf:type schema:CreativeWork
170 sg:pub.10.1023/a:1016377114477 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008981868
171 https://doi.org/10.1023/a:1016377114477
172 rdf:type schema:CreativeWork
173 https://app.dimensions.ai/details/publication/pub.1078798623 schema:CreativeWork
174 https://app.dimensions.ai/details/publication/pub.1081946813 schema:CreativeWork
175 https://doi.org/10.1002/1097-0142(19860415)57:8+<1648::aid-cncr2820571303>3.0.co;2-o schema:sameAs https://app.dimensions.ai/details/publication/pub.1012261851
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1016/0003-9861(83)90118-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043004064
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1016/0167-5699(85)90159-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017875411
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/0306-3623(86)90017-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005628349
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/0306-3623(86)90189-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001818489
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/0378-5173(86)90168-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044279461
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1084/jem.121.6.901 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040893216
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1089/cdd.1984.1.337 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059243547
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1113/expphysiol.1962.sp001620 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031555789
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1248/bpb1978.7.59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005279663
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1248/bpb1978.8.206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011665258
196 rdf:type schema:CreativeWork
197 https://www.grid.ac/institutes/grid.417570.0 schema:alternateName Roche (Switzerland)
198 schema:name Central Research Units, F. Hoffmann-La Roche & Co. Ltd, Basel, Switzerland
199 Pharmaceutical Research/Preclinical Development, F. Hoffmann-La Roche & Co. Ltd, Basel, Switzerland
200 rdf:type schema:Organization
201 https://www.grid.ac/institutes/grid.418234.8 schema:alternateName Basilea Pharmaceutica (Switzerland)
202 schema:name Basel Institute for Immunology, Basel, Switzerland
203 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...